A novel pyrido-thieno-pyrimidine derivative activates p53 through induction of phosphorylation and acetylation in colorectal cancer cells

International Journal of Oncology

Volumn 46, Issue 1, 2015, Pages 342-350

  Kang, Mi Ae ^a   Kim, Mi Sook ^a   Kim, Ji Young ^a   Shin, Young Joo ^b   Song, Jie Young ^a   Jeong, Jae Hoon ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Acetylation; Colorectal cancer; ERK1 2; MDM2; P300; P53; Phosphorylation

Indexed keywords

ANTINEOPLASTIC AGENT; N-(2-(DIMETHYLAMINO)ETHYL)-2,3-DIMETHYL-4-OXO-4H-PYRIDO(1,2-A)THIENO(2,3-D)PYRIMIDINE-9-CARBOXAMIDE; PROTEIN P53; PYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; THIOPHENE DERIVATIVE; TP53 PROTEIN, HUMAN;

ACETYLATION; AGONISTS; COLORECTAL TUMOR; DRUG EFFECTS; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING;

ACETYLATION; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIMIDINES; PYRIMIDINONES; THIOPHENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84917690944     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2720     Document Type: Article

References (32)

1. Vousden KH: p53: Death Star. Cell 103: 691-694, 2000.
2. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
3. Juven T, Barak Y, Zauberman A, George DL and Oren M: Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8: 3411-3416, 1993.
4. Barak Y, Juven T, Haffner R and Oren M: mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461-468, 1993.
5. Miyashita T, Harigai M, Hanada M and Reed JC: Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131-3135, 1994.
6. Banin S, Moyal L, Shieh SY, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y and Ziv Y: Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674-1677, 1998.
7. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C and Abraham RT: A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 13: 152-157, 1999.
8. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8: 282-288, 2002.
9. Miyachi M, Kakazu N, Yagyu S, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tsuchiya K, Iehara T and Hosoi H: Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res 15: 4077-4084, 2009.
10. Dai F, Chen Y, Song Y, Huang L, Zhai D, Dong Y, Lai L, Zhang T, Li D, Pang X, Liu M and Yi Z: A natural small molecule Harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells. PLoS One 7: e52162, 2012.
11. Zhang Q, Zeng SX, Zhang Y, Zhang Y, Ding D, Ye Q, Meroueh SO and Lu H: A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med 4: 298-312, 2012.
12. Jain KS, Chitre TS, Miniyar PB, Kathiravan MK, Bendre VS, Veer VS, Shahane SR and Shishoo CJ: Biological and medicinal significance of pyrimidines. Curr Sci 90: 793-803, 2006.
13. Zhang N, Ayral-Kaloustian S, Nguyen T, Hernandez R and Beyer C: 2-Cyanoaminopyrimidines as a class of antitumor agents that promote tubulin polymerization. Bioorg Med Chem Lett 17: 3003-3005, 2007.
14. Cocco MT, Congiu C, Lilliu V and Onnis V: Synthesis and in vitro antitumoral activity of new hyrazinopyriminide-5-carbonitrile derivatives. Bioorg Med Chem 14: 366-372, 2006.
15. Cocco MT, Congiu C, Lilliu V and Onnis V: Synthesis of new N-(2-(trifluoromethyl)pyridine-yl)anthranilic acid derivatives and their evaluation as anticancer agents. Bioorg Med Chem Lett 14: 5787-5791, 2004.
16. Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical stratagies. Nat Rev Cancer 3: 330-338, 2003.
17. Lim MJ, Ahn JY, Han Y, Yu CH, Kim MH, Lee SL, Lim DS and Song JY: Acriflavine enhances radiosensitivity of colon cancer cells through endoplasmic reticulum stress-mediated apoptosis. Int J Biochem Cell Biol 44: 1214-1222, 2012.
18. Harris SL and Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908, 2005.
19. Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997.
20. Demidenko ZN, Korotchkina LG, Gudkov AV and Blagosklonny MV: Paradoxical suppression of cellular senescence by p53. Proc Natl Acd Sci USA 107: 9660-9664, 2010.
21. Hofseth LJ, Hussain SP and Harris CC: p53: 25 years after its discovery. Trends Pharmacol 25: 177-181, 2004.
22. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV and Blagosklonny MV: The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany, NY) 2: 344-352, 2010.
23. Melnikova VO, Santamaria AB, Bolshakov SV and Ananthaswamy HN: Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase. Oncogene 22: 5958-5966, 2003.
24. Persons DL, Yazlovitskaya EM and Pelling JC: Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 275: 35778-35785, 2000.
25. She QB, Chen N and Dong Z: ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J Biol Chem 275: 20444-20449, 2000.
26. Kubbutat MH, Jones SN and Vousden KH: Regulation of p53 stability by Mdm2. Nature 387: 299-303, 1997.
27. Maltzman W and Czyzyk L: UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4: 1689-1694, 1984.
28. Ashcroft M, Taya Y and Vousden KH: Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 20: 3224-3233, 2000.
29. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E and Yao TP: p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20: 1331-1340, 2001.
30. Kuroda T, Murayama A, Katagiri N, Ohta Y, Fujita E, Masumoto H, Ema M, Takahashi S, Kimura K and Yanagisawa J: RNA content in the nucleolus alters p53 acetylation via MYBBP1A. EMBO J 30: 1054-1066, 2011.
31. Barneda-Zahonero B and Parra M: Histone deacetylases and cancer. Mol Oncol 6: 579-589, 2012.
32. V aziri H, Dessain SK, Eaton EN, Imai SI, Frye RA, Pandita TK, Guarente L and Weinberg RA: hSIR2SIRT1 functions as an NAD-dependent p53 deacetylation. Cell 107: 149-159, 2001.